Publications, Pharmaceutical

Aptar Pharma Q&A on trends and challenges in nasal drug delivery

Nasal drug delivery is currently the focus of considerable drug development activity.

This Q&A takes a detailed look at the nasal drug delivery landscape and the potential of this route for the delivery of vaccines and therapeutics for COVID-19, for nose-to-brain drug delivery and for improving the accessibility of emergency medications. Key challenges associated with the development of nasal drug products are outlined along with factors impacting device design and selection.
The regulatory landscape is also considered. Barriers to the development of nasal drug delivery products are examined but it is concluded that the route has a bright future with considerable potential to address currently unmet therapeutic needs.

Download the Q&A
Author(s): Dr Julie D. Suman
21 Apr 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

26 May 2020

Aptar Pharma discusses Article 117 of the Medical Device Regulations

Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
12 May 2020

Devices & Services for Lifecycle Management of Crisis Medications and Beyond

Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Product Solutions

Read More
1 May 2020

Supporting Improved Patient Onboarding and Adherence with Training Solutions

Publications, Pharmaceutical, Device Innovations, Product Solutions, Innovation & Insights

Read More
21 Apr 2020

Using in vitro dissolution tests for local bioequivalence in OINDPs

Webinars, Pharmaceutical, Innovation & Insights, Market Insights

Read More
1 16 17 18 19 20 22

Request Access


Requesting access to Aptar Pharma Q&A on trends and challenges in nasal drug delivery.

  • This field is for validation purposes and should be left unchanged.
Back To Top